Generate Biomedicines

GENB · NASDAQ

$12.90+$0.34 (+2.71%)TodayMarket closed · Oct 20, 7:57 PM ET

Prev close $12.56

GENB analyst rating

BuyConsensus of 6 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy6
Hold0
Underperform0
Sell0

12-month price target · 7 analysts

Average $27.54 (+113.5% upside)

Low: $22.22
Now: $12.90
High: $31.50

Upgrades and downgrades

The latest rating actions, newest first

GENB analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Oct 5, 2026	Maintains	Buy	$30.00	32%
HC Wainwright & Co.	Sep 8, 2026	Maintains	Buy	$30.00	32%
HC Wainwright & Co.	Aug 28, 2026	Maintains	Buy	$25.00 → $30.00	32%
Morgan Stanley	May 14, 2026	Maintains	Overweight	$20.00 → $22.00	47%
HC Wainwright & Co.	May 8, 2026	Maintains	Buy	$16.00 → $25.00	32%
HC Wainwright & Co.	Apr 13, 2026	Initiates	Buy	$16.00	32%
Goldman Sachs	Mar 24, 2026	Initiates	Buy	$26.00	47%
Morgan Stanley	Mar 24, 2026	Initiates	Overweight	$20.00	47%
Piper Sandler	Mar 24, 2026	Initiates	Overweight	$24.00	40%
Cantor Fitzgerald	Mar 24, 2026	Initiates	Overweight	—	34%

The case for and against

Updated Oct 18, 2026

Bull case

Generate Biomedicines is compelling because its Generate Platform uses machine learning to design novel protein therapeutics on demand, creating a scalable discovery engine that could produce differentiated medicines across multiple modalities with unusually fast iteration. The first-patient dosing of GB-5267 in a Phase 1 autologous MUC16-directed, IL-18-armored CAR-T study adds early oncology optionality, while GB-0895’s Phase 1 data in 96 asthma participants and 40 COPD participants showed durable pharmacodynamic suppression for at least 6 months with no treatment-related serious adverse events. Together, these programs support a positive outlook by combining platform breadth, clinical validation, and a potentially commercially advantageous semiannual dosing profile that may stand out versus monthly biologic competition.

Bear case

Generate Biomedicines is viewed negatively because its valuation is heavily dependent on a single lead asset, GB-0895, even though the model only assigns an 80% probability of launch in asthma and 35% in COPD, leaving material clinical and regulatory execution risk. The investment case also hinges on assumptions of a 2029 launch and peak sales of about $2.4B and $2.0B, while Phase 3 enrollment or efficacy failure, loss of semiannual dosing durability, and stronger-than-expected competition could sharply impair that outcome. Although the analysis cites an estimated enterprise value of roughly $4.9B and no debt as of end-3Q27, the company still faces medium- to long-term dilution risk and trading volatility tied to short interest and lock-up-related float changes.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.